Literature DB >> 7543919

Graded changes in the response of individual human basophils to stimulation: distributional behavior of events temporally coincident with degranulation.

D W MacGlashan1.   

Abstract

Human basophils, stimulated with either anti-IgE antibody or formyl-methionine-leucine-phenylalanine, were examined by two measures of the cell response that may reflect degranulation. Flow cytometric measurement of either of these two measures, changes in forward scatter intensity (an indirect measure of the basophil size) or changes in the intensity of acridine orange-loaded cells (which labels basophil granules), allowed an assessment of the distribution of single cell responses. With regard to the latter technique, structures that appeared to be basophil granules were shown to metachromatically label with low concentrations of acridine orange, which has little or no effect on histamine release. During stimulation these labeled granules were lost, leading to decreased fluorescence. Changes in either the forward scatter parameter or acridine orange labeling occurred on the same time scale as histamine release, differentiating these measures of the basophil response from early signal transduction events. Challenging basophils with a combination of phorbol myristate acetate and ionomycin caused 100% histamine release and allowed a measurement of the maximum change in forward scatter intensity or loss of acridine orange labeling. The flow cytometric distributions after this treatment were then compared with the distributions obtained by challenging cells with several concentrations of anti-IgE antibody or formyl-methionine-leucine-phenylalanine, which induced various submaximal responses. These flow cytometric distributions demonstrated that single cells could be found in intermediate states of activation, i.e., the response of all cells was graded according to the strength of the stimulus. These studies lead to the general conclusion that all aspects of the basophil response, including those late events in the basophil response we have studied here, as well as early events that we have studied previously, are graded in a continuous manner, according to the magnitude of the stimulus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7543919     DOI: 10.1002/jlb.58.2.177

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  6 in total

Review 1.  Assessing basophil functional measures during monoclonal anti-IgE therapy.

Authors:  Sarbjit S Saini; Donald W MacGlashan
Journal:  J Immunol Methods       Date:  2012-06-01       Impact factor: 2.303

2.  Marked differences in the signaling requirements for expression of CD203c and CD11b versus CD63 expression and histamine release in human basophils.

Authors:  Donald MacGlashan
Journal:  Int Arch Allergy Immunol       Date:  2012-06-20       Impact factor: 2.749

Review 3.  Immunotherapy in allergy and cellular tests: state of art.

Authors:  Salvatore Chirumbolo
Journal:  Hum Vaccin Immunother       Date:  2014-05-02       Impact factor: 3.452

4.  Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes.

Authors:  D MacGlashan
Journal:  Clin Exp Allergy       Date:  2010-07-13       Impact factor: 5.018

5.  Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis.

Authors:  Kaori Mukai; Nicolas Gaudenzio; Sheena Gupta; Nora Vivanco; Sean C Bendall; Holden T Maecker; Rebecca S Chinthrajah; Mindy Tsai; Kari C Nadeau; Stephen J Galli
Journal:  J Allergy Clin Immunol       Date:  2016-07-15       Impact factor: 10.793

6.  Lowering Etoposide Doses Shifts Cell Demise From Caspase-Dependent to Differentiation and Caspase-3-Independent Apoptosis via DNA Damage Response, Inducing AML Culture Extinction.

Authors:  Emanuele Bruni; Albrecht Reichle; Manuel Scimeca; Elena Bonanno; Lina Ghibelli
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.